Antagonist/Agonist Balance of the Nonsteroidal Antiandrogen Bicalutamide (Casodex) in a New Prostate Cancer Model

Publisher： Karger

E-ISSN： 1423-0399|65|2|73-79

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.65, Iss.2, 2000-10, pp. : 73-79

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multimodality Treatment of Gynecomastia in Patients Receiving Antiandrogen Therapy for Prostate Cancer in the Era of Abiraterone Acetate and New Antiandrogen Molecules

By  

Oncology, Vol. 84, Iss. 2, 2012-11 ,pp. : 92-99

Karger

Access to resources Recommend Favorite

Non‐steroidal antiandrogen monotherapy compared with luteinizing hormone‐releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review

By  

BJU INTERNATIONAL, Vol. 116, Iss. 1, 2015-07 ,pp. : 30-36

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antiandrogen Monotherapy: Recommendations for the Treatment of Prostate Cancer

By  

Urologia Internationalis, Vol. 72, Iss. 2, 2004-02 ,pp. : 91-98

Karger

Access to resources Recommend Favorite

Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program

By  

Oncology, Vol. 65, Iss. 1, 2003-09 ,pp. : 1-4

Karger

Access to resources Recommend Favorite

Prostate-Specific Antigen Dynamics Predict Risk of Progression in Advanced Prostate Cancer Treated with Bicalutamide plus Castration

By  

Urologia Internationalis, Vol. 68, Iss. 4, 2002-05 ,pp. : 220-225

Karger

Access to resources Recommend Favorite